Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Safety Info. Calls for Caution on Pulmonary Hypertension Associated with Glivec
November 30, 2012
- FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
- Switch OTC Version of Ebastine Recommended for Approval
November 28, 2012
- BIKEN Exits New Flu Vaccine Development Project, MHLW to Invite Other Makers
November 26, 2012
- LDP Policy Statement Calls for Perpetuation of New Drug Premium, Promotion of Switch-OTC Drugs
November 26, 2012
- MHLW Approves Additional Indications for 3 APIs/5 Products, Including Botox
November 26, 2012
- Even Non-Welfare Beneficiaries Have No Obligation to Use of Generics: Health Minister Mitsui
November 22, 2012
- MHLW Set to Clarify Review Procedures for Companion Diagnostics
November 21, 2012
- Translational Research, Biobank Projects Require Drastic Revision: Project Screening
November 21, 2012
- PAFSC’s 2nd Committee to Review 7th Biopharmaceutical RA Drug on Nov. 29
November 20, 2012
- PAFSC’s 1st Committee to Review 7 Products Including BMKK’s Apixaban on Nov. 30
November 20, 2012
- Re-Pricing of Generic Drugs Added to GRU’s Recommendation: Project Screening
November 20, 2012
- GRU to Propose that Welfare Beneficiaries Be Required to Use Generics as a Rule
November 20, 2012
- Temporary Halts in Generic Product Marketing, JGA Accelerates Efforts in Collecting Information
November 19, 2012
- Average Foreign Price Adjustment Results in NHI Price Lower than Manufacturing Cost for Pfizer Japan’s Tygacil: CSIMC
November 16, 2012
- CSIMC Subcommittee Eyes Price Cuts for Long-Listed Drugs with Slow Generic Penetration
November 16, 2012
- CSIMC OKs Listing for 15 APIs/22 Products; Peak Sales Estimated at 32.6 Billion Yen for Lotriga
November 15, 2012
- MHLW Director Suggests Being Ready for Increased Official Management if 3rd Round of Distribution Reform Fails
November 14, 2012
- Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
- Hodanren Asks MHLW to Disclose Discussions by Members of Drug Pricing Organization
November 13, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…